Regenerative Medicine Market worth $62.69 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global regenerative medicine market will grow from USD 23.90 billion in 2026 to USD 62.69 billion by 2031, a 21.3% CAGR; North America held about 52.3% of the market in 2025. The report cites funding and commercial momentum, including USD 115 million raised by Aspect Biosystems and USD 102 million secured by Neurona Therapeutics in 2025, alongside large acquisitions: Gilead completed its approximately USD 7.8 billion Arcellx acquisition and UCB acquired Neurona for potential consideration of up to USD 1.15 billion. Growth prospects are positive, though Gilead cell therapy revenue declined 7% to USD 1.8 billion in 2025 amid competition.

Analysis

The forecast is a category-level demand claim, not an earnings bridge: broad market definitions can include clinical-stage activity and products with very different commercial economics. Do not capitalize the headline growth rate into sector multiples without evidence of net pricing, reimbursement, treatment-center throughput, and repeatable manufacturing yields. Value should accrue disproportionately to therapies already scaling commercially and to manufacturers that can expand output without compromising quality—not evenly across the named companies.

Near term, the useful signal is competitive share migration within CAR-T. Johnson & Johnson and Bristol Myers Squibb have commercial products to demonstrate volume and capacity execution; Gilead’s acquired pipeline may improve its longer-term position, but does not by itself reverse weakness in existing cell-therapy revenue. Gilead’s acquisition of Arcellx also means ACLX is not a standalone exposure to the thesis. UCB’s Neurona asset is a longer-dated, clinical and milestone-dependent option, not proof of near-term regenerative-therapy revenue.

Over 6–18 months, manufacturing throughput, site expansion, safety, and reimbursement are likelier stock drivers than broad TAM estimates. Better preservation technology could ease cold-chain constraints and expand access, while also reducing a potential logistics advantage; the funding announcement does not establish commercial viability. The contrarian point: investors may overread market growth as broad-based earnings growth. Failure to convert demand into profitable volume—or safety/regulatory setbacks—could compress valuations even as the category expands.

Key Decisions for Investors

• Avoid a broad regenerative-medicine basket trade on this forecast alone. Treat it as a watchlist catalyst; the report does not establish realized demand, margins, or forecast methodology.
• Prefer relative exposure to commercial execution over pre-commercial optionality: monitor JNJ and BMY for quarterly cell-therapy growth, capacity utilization, and margin disclosure. Reassess if growth stalls or management identifies manufacturing or reimbursement constraints.
• Keep GILD as a conditional, not automatic, beneficiary: track cell-therapy sales trends and evidence that anito-cel can scale after integration. A continued decline in established products without offsetting pipeline contribution would falsify the recovery case.
• For UCB, treat Neurona as long-duration pipeline optionality; verify clinical milestones, regulatory progress, and milestone economics before assigning material value. Any safety signal or development delay weakens the thesis.